Zusamen Lifesciences & Research Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 2.00 Cr
as on 17-07-2024
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 16.08 Cr
as on 17-07-2024
- Revenue 239.43%
(FY 2023)
- Profit 56.53%
(FY 2023)
- Ebitda 58.63%
(FY 2023)
- Net Worth -1126.74%
(FY 2023)
- Total Assets -3.16%
(FY 2023)
About Zusamen Lifesciences & Research
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹16.08 Cr.
Amar Rajaram, Umesh Parge, and Abhay Parge serve as directors at the Company.
- CIN/LLPIN
U24233PN2014PTC150247
- Company No.
150247
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jan 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Satara, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Zusamen Lifesciences & Research?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Umesh Parge  | Director | 20-Jan-2014 | Current |
| Amar Rajaram | Director | 20-Jan-2014 | Current |
| Abhay Parge | Director | 20-Jan-2014 | Current |
Financial Performance of Zusamen Lifesciences & Research.
Zusamen Lifesciences & Research Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 239.43% increase. The company also saw a substantial improvement in profitability, with a 56.53% increase in profit. The company's net worth observed a substantial decline by a decrease of 1126.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zusamen Lifesciences & Research?
In 2023, Zusamen Lifesciences & Research had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PVT_LTD.webp)
Libra Drugs (India) Pvt LtdActive 32 years 4 monthsAmar Rajaram, Umesh Parge and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 23 Nov 2017 | ₹5.00 Cr | Open |
Bank Of India Creation Date: 23 Nov 2017 | ₹2.61 Cr | Open |
Bank Of India Creation Date: 16 Jun 2016 | ₹1.61 Cr | Open |
How Many Employees Work at Zusamen Lifesciences & Research?
Unlock and access historical data on people associated with Zusamen Lifesciences & Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zusamen Lifesciences & Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zusamen Lifesciences & Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
